Acute schistosomiasis in travellers: outcomes of a short-course therapy
Journal of Travel Medicine · 2025
DOI: 10.1093/jtm/taaf065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Travel Medicine, 2025. Verfasst von Jan Clerinx und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Belgium; 155, Nationalestraat; 2000 Antwerp, Belgium. Hauptthemen laut MEDLINE: Praziquantel, Methylprednisolone, Schistosomiasis, Travel. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Institute of Tropical Medicine.
Abstract (Originalsprache)
Background
Therapy of acute schistosomiasis in travellers currently relies on poorly consistent combinations of corticosteroids and praziquantel. In a cluster of travellers recently infected with Schistosoma mattheei × Schistosoma haematobium hybrids during a trip to South Africa in 2017, we evaluated the safety and efficacy of short methylprednisolone cycles to suppress early symptoms and of a single-day praziquantel/methylprednisolone administration at well-defined time lapses.
Methods
Symptomatic patients seen during the early phase, 4 to 5 weeks (week 4–5) after infection, were given oral methylprednisolone 0.5 mg/kg once daily in one or more cycles of three consecutive days until symptoms abated. Patients were seen again at week 7–8 to be given praziquantel 40 mg/kg in two divided doses 2 hours apart, followed by a single dose of oral methylprednisolone 0.5 mg/kg 2 hours later to prevent symptom exacerbation. All patients were reevaluated for symptoms and infection at week 12–14, using serum circulating anodic antigen (CAA) as a marker of active infection.
Results
A total of 34 infected individuals were longitudinally followed up. Of these, 21 patients with symptoms at presentation (week 4–5) were given methylprednisolone. Symptoms abated during the first three-day cycle in 15/21 (71%), during the second cycle in another 4/21 (19%), and during the third cycle in the remaining 2/21 (10%). All 34 participants were treated with the praziquantel/steroid combination at week 7–8; 9 (26%) had mild symptoms of short duration. Only 4 (12%) developed fever and needed 1 or 2 additional days of steroids. At week 12–14, serum CAA remained detectable in only one of the 34 participants.
Conclusion
In most patients, a single three-day course of methylprednisolone was sufficient to suppress symptoms of acute schistosomiasis. Only few patients experienced short lived symptom exacerbation after taking a single-day praziquantel and methylprednisolone combination at 7–8 weeks following exposure. Infection was cleared in almost all cases 4–6 weeks later.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Belgium; 155, Nationalestraat; 2000 Antwerp, Belgium.
ORCID-Profile: Emmanuel Bottieau
Förderung
- Institute of Tropical Medicine
Zitieren
APA
Clerinx, J., Maniewski, U., Van Den Broucke, S., Soentjens, P., Cnops, L., Van Esbroeck, M., & Bottieau, E. (2025). Acute schistosomiasis in travellers: outcomes of a short-course therapy. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taaf065
Vancouver
Clerinx J, Maniewski U, Van Den Broucke S, Soentjens P, Cnops L, Van Esbroeck M, et al. Acute schistosomiasis in travellers: outcomes of a short-course therapy. Journal of Travel Medicine. 2025. doi:10.1093/jtm/taaf065
BibTeX
@article{Clerinx2025,
author = {Clerinx, Jan and Maniewski, Ula and Van Den Broucke, Steven and Soentjens, Patrick and Cnops, Liselotte and Van Esbroeck, Marjan and Bottieau, Emmanuel},
title = {Acute schistosomiasis in travellers: outcomes of a short-course therapy},
journal = {Journal of Travel Medicine},
year = {2025},
doi = {10.1093/jtm/taaf065}
}
EUVIMED